Cross-presentation of tumor-specific antigens by tumor-derived EVs can be downregulated, while suppression of T cell activation is often promoted through overexpression of PD-L1, which interacts with PD-1 receptor on T cells to elicit the immune checkpoint response. The gene discussed is CD274; the disease is neoplasm.